The oxidation products of transition metal complexes with porphyrin are being examined currently by many research groups. meso-
5,10,15,20-tetrakis(2,5-Dimethoxyphenyl)porphyrin [T(2,5-(OCH3)2)PP] and its coordination compound with oxovanadium(IV) resulting
in VO[T(2,5-(OCH3)2)PP] were prepared by the standard procedures. The resulting complex was characterized with or without the
addition of antimony pentachloride by infrared (IR) spectroscopy, electron paramagnetic resonance (EPR) spectroscopy and cyclic
voltammetry (CV). The UV-visible absorption spectrum of porphyrin ligand-based oxidation of vanadyl porphyrin VO[T(2,5-(OCH3)2)PP]
in the presence of 0.5 mM SbCl5 has shown bands at 425, 540 and 650 nm. The final electro-oxidation product has a broad absorption
band centered at 650 nm. It is characteristic of a porphyrin mono- cation which is seen due to oxidation at 0.0995V of ΔE value in the
cyclic voltammogram of VO[T(2,5-(OCH3)2)PP]. These spectral features observed during the oxidation are in good agreement with the
stepwise formation of mono-cation radical and di-cation. The EPR spectrum of VO[T(2,5-(OCH3)2)PP] suggests that it could be oxidized
to the radical cation by oxidation with SbCl5 in dichloromethane. A radical cation is observed at low temperature and this spectrum corresponds
to monomeric π-cation radical. A spectrum of fifteen lines is observed on the further addition of SbCl5 in dichloromethane. Thus, monomeric
π-cation radical is recognized as [VO(TPP)]+. It is confirmed by the appearance of a new band at 1275 cm-1 in the IR spectrum. Zero field
splitting (ZFS) was calculated from the triplet state on the EPR spectrum. It is suggested that ZFS interaction occurs from the dipolar
coupling between the two electrons.
Keywords: meso-Vanadyl porphyri
A porphyrin compound manganese(III) meso-5,10,15,20-tetrakis(4-pyridyl)porphyrin, Mn(Py)4P
containing manganese(III) and 4-pyridyl ligands was synthesized. The UV-visible spectrophotometry
and cyclic voltammetry were used to investigate the axial ligand and the redox behaviours of Mn(Py)4P.
This study investigates the reduction properties of Mn(Py)4P using primary amine, imidazole and
2-methylimidazole as axial ligands. Reduction of Mn(Py)4P leads to a shift in absorption bands,
indicating the conversion from manganese(III) to manganese(II) porphyrin. The addition of primary
amine results in a square pyramidal structure for Mn(II) porphyrin, while imidazole or
2-methylimidazole leads to the formation of tetragonal complexes. These changes in geometry result in
a decrease in π-bonding. The observed spectral patterns support the involvement of axial ligands in the
5th and 6th positions of manganese(III) porphyrin. The cyclic voltammogram confirmed the alteration
in geometry, indicating changes in the redox properties of compound. As a whole, the results of this
study provide light on the ways where the behaviour of in which Mn(Py)4P can be altered by the
presence of other molecules.
In this work, meso-tetrakis(p-Hydroxyphenyl) porphyrin [T(p-OH)PP] and manganese(III)
meso-tetrakis(p-hydroxyphenyl) porphyrin Mn[T(p-OH)PP] were synthesized and characterized. The
UV-visible and cyclic voltammetry were used to evaluate the axial ligand and redox behaviour of
Mn[T(p-OH)PP]. The addition of ethylamine, diethylamine and tertiary amines to Mn(III)
meso-porphyrins distinguishes their axial ligand characteristics. The presence of ethylamine causes
the octahedral geometry to transform into a square pyramidal structure. Cyclic voltammetry shows
that Mn(III) converts to Mn(II) porphyrins. Additionally, the UV-visible spectrophotometry and cyclic
voltammetry were also used to investigate the oxidation process.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.